Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Indian Journal of Forensic Medicine and Toxicology ; 15(4):353-358, 2021.
Article in English | EMBASE | ID: covidwho-1444743

ABSTRACT

Background: Corona virus disease 2019 (COVID-19) pandemic need urgent measurement and correlation of laboratory parameters in severe and non-severe cases. Serum ferritin, folic acid, vitamin B12, C-reactive protein, D-dimer and homocysteine was measured in patients who were infected with COVID-19. Aim of the Study: To evaluate the usefulness of serum ferritin, folate, B12, C-reactive protein, D-dimer and homocysteine level as biomarkers for prediction of patients with severe and critical COVID-19 infection. Subject, Material, Method: A cross sectional study was conducted at AL-Kindy hospital, Baghdad, Iraq from October 2020 to December 2020. Serum ferritin, folate, Vitamin B12, C-reactive protein, homocysteine and blood D-dimer were measured in 88 patients who suffered from COVID-19 infection, 50 cases with severe infection and 38 with non-severe infection. The age range of patients between 20-59 years old. Samples were collected from AL-Kindy hospital, Baghdad. Result: Serum folic acid was significantly low in severe group than in non-severe group, while serum ferritin, CRP and blood D-dimer were high in severe group than in non-severe group. Conclusion: In this study, measurement of serum ferritin, CRP and blood D-dimer were important in follow up of patients who infected with the novel virus as the level of them were higher in severe than in non-severe cases. Folic acid has role in determining the severity of COVID-19 infection bacause level was low in patients with severe than non-severe infection.

2.
European Observatory on Health Systems and Policies. European Observatory Policy Briefs ; 2021.
Article in English | MEDLINE | ID: covidwho-1196319

ABSTRACT

COVID-19 can cause persistent ill-health. Around a quarter of people who have had the virus experience symptoms that continue for at least a month but one in 10 are still unwell after 12 weeks. This has been described by patient groups as "Long COVID". Our understanding of how to diagnose and manage Long COVID is still evolving but the condition can be very debilitating. It is associated with a range of overlapping symptoms including generalized chest and muscle pain, fatigue, shortness of breath, and cognitive dysfunction, and the mechanisms involved affect multiple system and include persisting inflammation, thrombosis, and autoimmunity. It can affect anyone, but women and health care workers seem to be at greater risk. Long COVID has a serious impact on people's ability to go back to work or have a social life. It affects their mental health and may have significant economic consequences for them, their families and for society. Policy responses need to take account of the complexity of Long COVID and how what is known about it is evolving rapidly. Areas to address include: The need for multidisciplinary, multispecialty approaches to assessment and management;Development, in association with patients and their families, of new care pathways and contextually appropriate guidelines for health professionals, especially in primary care to enable case management to be tailored to the manifestations of disease and involvement of different organ systems;The creation of appropriate services, including rehabilitation and online support tools;Action to tackle the wider consequences of Long COVID, including attention to employment rights, sick pay policies, and access to benefit and disability benefit packages;Involving patients both to foster self-care and self-help and in shaping awareness of Long COVID and the service (and research) needs it generates;and Implementing well-functioning patient registers and other surveillance systems;creating cohorts of patients;and following up those affected as a means to support the research which is so critical to understanding and treating Long COVID.

3.
Public Health ; 185: A1-A2, 2020 08.
Article in English | MEDLINE | ID: covidwho-693082
SELECTION OF CITATIONS
SEARCH DETAIL